Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 10, 2005

View Archived Issues

New data on the effects of topical ATL-1101 in mild to moderate psoriasis

Bazedoxifene's actions in animal models of osteoporosis

In vitro data on laquinimod, an experimental drug for MS

Adventrx inlicenses novel emulsion formulation of vinorelbine tartrate

Rejuvenon renames itself Sapphire Therapeutics

ChemGenex studies Ceflatonin in Gleevec-resistant CML

Provectus cleared for phase I study of PV-10 for recurrent breast cancer

Positive phase III data for ALGRX-3268 local anesthetic

ActivBiotics to study rifalazil for PAD in phase III trial

Telik to begin clinical studies with oral Telintra

Phase III program begins for tobramycin inhalation powder in cystic fibrosis

Genzyme licenses CML markers from UCLA

GenVec and Vaccine Research Center HIV research program boosted by investment

Aastrom Biosciences begins clinical trials with Tissue Repair Cells for limb ischemia

Cerus and The University of New Mexico to develop tularemia vaccine

Trillium gains immunology-related portfolio through Arthron acquisition

Reliant announces U.S. launch of Omacor as diet supplement for very high TG

BioArctic and Abmaxis establish alliance for Alzheimer's disease

Comparative study of retapamulin's antimicrobial activity

Mechanisms underlying Valortim's potency and durability against anthrax

Lilly profiles mGlu2/3 receptor agonist parent and prodrug studies

Neuroprotective effects of NAP in MS

Recent patents cover novel treatments for Parkinson's disease, Alzheimer's disease, etc.

New therapeutics for cancer claimed in recent patents

Therapeutics and diagnostics for arthritis in early development

Promising results reported for LB-03002 in children with GHD

Gardasil reported to reduce the risk of HPV-associated cervical neoplasia

New data on the role of mGlu receptors in schizophrenia and anxiety disorders

Davanat increases the antitumor efficacy of 5-FU in patients with solid tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
FDA greenlights Medtronic Onyx subdural hematoma treatment
BioWorld MedTech
Sometimes the darkest products (names) bring a bright spot of news to their developers, as the U.S. FDA clearance for Galway, Ireland-based Medtronic plc's Onyx...